Spectrum Pharmaceuticals has signed a letter of agreement with Viropro to develop a biosimilar version of Genentech / Roche’s monoclonal antibody drug rituximab.
The deal seeks to capitalise on patent expirations for Rituximab, which achieved worldwide sales of about $5.6 billion in 2009.
Biosimilars, also known as follow-on biologics, are officially-approved versions of biopharmaceutical products made by a different company following patent and exclusivity expiry of the innovator product.
How well do you really know you competitors?
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData